Search

Your search keyword '"Kuster, Gabriela M."' showing total 229 results
Start Over Author "Kuster, Gabriela M."
229 results on '"Kuster, Gabriela M."'

3. Development and validation of a prognostic model for the early identification of COVID-19 patients at risk of developing common long COVID symptoms

Author

Deforth, Manja, Gebhard, Caroline E., Bengs, Susan, Buehler, Philipp K., Schuepbach, Reto A., Zinkernagel, Annelies S., Brugger, Silvio D., Acevedo, Claudio T., Patriki, Dimitri, Wiggli, Benedikt, Twerenbold, Raphael, Kuster, Gabriela M., Pargger, Hans, Schefold, Joerg C., Spinetti, Thibaud, Wendel-Garcia, Pedro D., Hofmaenner, Daniel A., Gysi, Bianca, Siegemund, Martin, Heinze, Georg, Regitz-Zagrosek, Vera, Gebhard, Catherine, and Held, Ulrike

Published
2022
Full Text
View/download PDF

5. Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020

Author

Gebhard, Caroline E, Sütsch, Claudia, Gebert, Pimrapat, Gysi, Bianca, Bengs, Susan, Todorov, Atanas, Deforth, Manja, Buehler, Philipp K, Meisel, Alexander, Schuepbach, Reto A, Zinkernagel, Annelies S, Brugger, Silvio D, Acevedo, Claudio, Patriki, Dimitri, Wiggli, Benedikt, Beer, Jürg H, Friedl, Andrée, Twerenbold, Raphael, Kuster, Gabriela M, Pargger, Hans, Tschudin-Sutter, Sarah, Schefold, Joerg C, Spinetti, Thibaud, Henze, Chiara, Pasqualini, Mina, Sager, Dominik F, Mayrhofer, Lilian, Grieder, Mirjam, Tontsch, Janna, Franzeck, Fabian C, et al, Gebhard, Caroline E, Sütsch, Claudia, Gebert, Pimrapat, Gysi, Bianca, Bengs, Susan, Todorov, Atanas, Deforth, Manja, Buehler, Philipp K, Meisel, Alexander, Schuepbach, Reto A, Zinkernagel, Annelies S, Brugger, Silvio D, Acevedo, Claudio, Patriki, Dimitri, Wiggli, Benedikt, Beer, Jürg H, Friedl, Andrée, Twerenbold, Raphael, Kuster, Gabriela M, Pargger, Hans, Tschudin-Sutter, Sarah, Schefold, Joerg C, Spinetti, Thibaud, Henze, Chiara, Pasqualini, Mina, Sager, Dominik F, Mayrhofer, Lilian, Grieder, Mirjam, Tontsch, Janna, Franzeck, Fabian C, and et al

Abstract

Background: Women are overrepresented among individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Biological (sex) as well as sociocultural (gender) differences between women and men might account for this imbalance, yet their impact on PASC is unknown. Aim: We assessed the impact of sex and gender on PASC in a Swiss population. Method: Our multicentre prospective cohort study included 2,856 (46% women, mean age 44.2 ± 16.8 years) outpatients and hospitalised patients with PCR-confirmed SARS-CoV-2 infection.ResultsAmong those who remained outpatients during their first infection, women reported persisting symptoms more often than men (40.5% vs 25.5% of men; p < 0.001). This sex difference was absent in hospitalised patients. In a crude analysis, both female biological sex (RR = 1.59; 95% CI: 1.41-1.79; p < 0.001) and a score summarising gendered sociocultural variables (RR = 1.05; 95% CI: 1.03-1.07; p < 0.001) were significantly associated with PASC. Following multivariable adjustment, biological female sex (RR = 0.96; 95% CI: 0.74-1.25; p = 0.763) was outperformed by feminine gender-related factors such as a higher stress level (RR = 1.04; 95% CI: 1.01-1.06; p = 0.003), lower education (RR = 1.16; 95% CI: 1.03-1.30; p = 0.011), being female and living alone (RR = 1.91; 95% CI: 1.29-2.83; p = 0.001) or being male and earning the highest income in the household (RR = 0.76; 95% CI: 0.60-0.97; p = 0.030). Conclusion: Specific sociocultural parameters that differ in prevalence between women and men, or imply a unique risk for women, are predictors of PASC and may explain, at least in part, the higher incidence of PASC in women. Once patients are hospitalised during acute infection, sex differences in PASC are no longer evident.

Published
2024

7. Myeloperoxidase: Reviving an old ally for immunomodulation in heart failure?

Author

Kuster, Gabriela M., Assmus, Birgit, and Mahfoud, Felix

Subjects
*BRAIN natriuretic factor, *HEART failure, *HEART diseases, *POST-translational modification, *HEART failure patients, *PLASMINOGEN activator inhibitors
Abstract

The article explores the potential use of myeloperoxidase (MPO) as a target for treating heart failure. MPO is an enzyme that is elevated in inflammatory conditions and cardiovascular disease. Recent studies have shown that inhibiting MPO can improve cardiac function in pre-clinical studies. The article also discusses a study that investigated the role of MPO in a mouse model of non-ischemic dilated cardiomyopathy and the potential benefits of MPO inhibition in heart failure patients. However, further research is needed to fully understand the role of MPO in human heart failure. The study suggests that MPO inhibition may have therapeutic potential in improving myocardial remodeling and function in different types of cardiomyopathies, but more clinical trials are needed to establish its efficacy. The study highlights the importance of finding new approaches to address the high disease burden and mortality associated with heart failure. [Extracted from the article]

Published
2024
Full Text
View/download PDF

10. Contributors

Author

Ágg, Bence, primary, Aghagolzadeh, Parisa, additional, Anene-Nzelu, Chukwuemeka George, additional, Backs, Johannes, additional, Barbé, Ferran, additional, Betsou, Fay, additional, Bezzina Wettinger, Stephanie, additional, Codreanu, Andrei, additional, Devaux, Yvan, additional, Dieterich, Christoph, additional, Durán, Javier, additional, Farrugia, Rosienne, additional, Felekkis, Kyriacos, additional, Ferdinandy, Péter, additional, Foo, Roger S-Y, additional, Galatou, Eleftheria, additional, de Gonzalo-Calvo, David, additional, Greco, Simona, additional, Grillari, Johannes, additional, Gunes, Hakan, additional, Hackl, Matthias, additional, Hamdani, Nazha, additional, Hein, Lutz, additional, Hermenegildo, Carlos, additional, Iglesias-Gutiérrez, Eduardo, additional, Izzi, Benedetta, additional, Jaquet, Kornelia, additional, Jusic, Amela, additional, Karađuzović-Hadžiabdić, Kanita, additional, Kuster, Gabriela M., additional, Madè, Alisia, additional, De Majo, Federica, additional, Martelli, Fabio, additional, Mügge, Andreas, additional, Ngo, Vivien, additional, Novella, Susana, additional, Paes, Ana Belén, additional, Papaneophytou, Christos, additional, Pedrazzini, Thierry, additional, Peters, Antje, additional, Pinilla, Lucía, additional, Robinson, Emma Louise, additional, Semmelrock, Elisabeth, additional, Stenzig, Justus, additional, Vanhaverbeke, Maarten, additional, Völkers, Mirko, additional, De Windt, Leon J., additional, Winkler, Johannes, additional, Xuereb Anastasi, Angela, additional, and Yilmaz, Mehmet Birhan, additional

Published
2021
Full Text
View/download PDF

12. TNF-α protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells

Author

Rolski, Filip, primary, Tkacz, Karolina, additional, Węglarczyk, Kazimierz, additional, Kwiatkowski, Grzegorz, additional, Pelczar, Paweł, additional, Jaźwa-Kusior, Agnieszka, additional, Bar, Anna, additional, Kuster, Gabriela M, additional, Chłopicki, Stefan, additional, Siedlar, Maciej, additional, Kania, Gabriela, additional, and Błyszczuk, Przemysław, additional

Published
2023
Full Text
View/download PDF

14. Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020.

Author

Gebhard, Caroline E., Sütsch, Claudia, Gebert, Pimrapat, Gysi, Bianca, Bengs, Susan, Todorov, Atanas, Deforth, Manja, Buehler, Philipp K., Meisel, Alexander, Schuepbach, Reto A., Zinkernagel, Annelies S., Brugger, Silvio D., Acevedo, Claudio, Patriki, Dimitri, Wiggli, Benedikt, Beer, Jürg H., Friedl, Andrée, Twerenbold, Raphael, Kuster, Gabriela M., and Pargger, Hans

Published
2024
Full Text
View/download PDF

15. TNF-α protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells.

Author

Rolski, Filip, Tkacz, Karolina, Węglarczyk, Kazimierz, Kwiatkowski, Grzegorz, Pelczar, Paweł, Jaźwa-Kusior, Agnieszka, Bar, Anna, Kuster, Gabriela M, Chłopicki, Stefan, Siedlar, Maciej, Kania, Gabriela, and Błyszczuk, Przemysław

Subjects
AUTOIMMUNE diseases, T cells, HEART failure, MYOCARDITIS, T cell receptors, HEART cells, CELL death
Abstract

Aims Tumour necrosis factor α (TNF-α) represents a classical pro-inflammatory cytokine, and its increased levels positively correlate with the severity of many cardiovascular diseases. Surprisingly, some heart failure patients receiving high doses of anti-TNF-α antibodies showed serious health worsening. This work aimed to examine the role of TNF-α signalling on the development and progression of myocarditis and heart-specific autoimmunity. Methods and results Mice with genetic deletion of TNF-α (Tnf +/− and Tnf −/−) and littermate controls (Tnf +/+) were used to study myocarditis in the inducible and the transgenic T cell receptor (TCRM) models. Tnf +/− and Tnf −/− mice immunized with α-myosin heavy chain peptide (αMyHC) showed reduced myocarditis incidence, but the susceptible animals developed extensive inflammation in the heart. In the TCRM model, defective TNF-α production was associated with increased mortality at a young age due to cardiomyopathy and cardiac fibrosis. We could confirm that TNF-α as well as the secretome of antigen-activated heart-reactive effector CD4+ T (Teff) cells effectively activated the adhesive properties of cardiac microvascular endothelial cells (cMVECs). Our data suggested that TNF-α produced by endothelial in addition to Teff cells promoted leucocyte adhesion to activated cMVECs. Analysis of CD4+ T lymphocytes from both models of myocarditis showed a strongly increased fraction of Teff cells in hearts, spleens, and in the blood of Tnf +/− and Tnf −/− mice. Indeed, antigen-activated Tnf −/− Teff cells showed prolonged long-term survival and TNF-α cytokine-induced cell death of heart-reactive Teff. Conclusion TNF-α signalling promotes myocarditis development by activating cardiac endothelial cells. However, in the case of established disease, TNF-α protects from exacerbating cardiac inflammation by inducing activation-induced cell death of heart-reactive Teff. These data might explain the lack of success of standard anti-TNF-α therapy in heart failure patients and open perspectives for T cell–targeted approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Regulatory RNAs in Heart Failure

Author

Gomes, Clarissa Pedrosa da Costa, Schroen, Blanche, Kuster, Gabriela M., Robinson, Emma L., Ford, Kerrie, Squire, Iain B., Heymans, Stephane, Martelli, Fabio, Emanueli, Costanza, and Devaux, Yvan

Published
2020
Full Text
View/download PDF

17. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19

Author

Sinnberg, Tobias, primary, Lichtensteiger, Christa, additional, Ali, Omar Hasan, additional, Pop, Oltin T., additional, Jochum, Ann-Kristin, additional, Risch, Lorenz, additional, Brugger, Silvio D., additional, Velic, Ana, additional, Bomze, David, additional, Kohler, Philipp, additional, Vernazza, Pietro, additional, Albrich, Werner C., additional, Kahlert, Christian R., additional, Abdou, Marie-Therese, additional, Wyss, Nina, additional, Hofmeister, Kathrin, additional, Niessner, Heike, additional, Zinner, Carl, additional, Gilardi, Mara, additional, Tzankov, Alexandar, additional, Röcken, Martin, additional, Dulovic, Alex, additional, Shambat, Srikanth Mairpady, additional, Ruetalo, Natalia, additional, Buehler, Philipp K., additional, Scheier, Thomas C., additional, Jochum, Wolfram, additional, Kern, Lukas, additional, Henz, Samuel, additional, Schneider, Tino, additional, Kuster, Gabriela M., additional, Lampart, Maurin, additional, Siegemund, Martin, additional, Bingisser, Roland, additional, Schindler, Michael, additional, Schneiderhan-Marra, Nicole, additional, Kalbacher, Hubert, additional, McCoy, Kathy D., additional, Spengler, Werner, additional, Brutsche, Martin H., additional, Maček, Boris, additional, Twerenbold, Raphael, additional, Penninger, Josef M., additional, Matter, Matthias S., additional, and Flatz, Lukas, additional

Published
2023
Full Text
View/download PDF

19. Defective Desmosomal Adhesion Causes Arrhythmogenic Cardiomyopathy by Involving an Integrin-αVβ6/TGF-β Signaling Cascade

Author

Schinner, Camilla, primary, Xu, Lifen, additional, Franz, Henriette, additional, Zimmermann, Aude, additional, Wanuske, Marie-Therès, additional, Rathod, Maitreyi, additional, Hanns, Pauline, additional, Geier, Florian, additional, Pelczar, Pawel, additional, Liang, Yan, additional, Lorenz, Vera, additional, Stüdle, Chiara, additional, Maly, Piotr I., additional, Kauferstein, Silke, additional, Beckmann, Britt M., additional, Sheikh, Farah, additional, Kuster, Gabriela M., additional, and Spindler, Volker, additional

Published
2022
Full Text
View/download PDF

23. NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction

Author

Cardiologie, Hart- en Vaatziekten Team A, Experimentele Afd. Cardiologie 1, Experimentele Afd. Cardiologie 2, Circulatory Health, Onderzoek Vrouw Hart & Vaatziekten, Xu, Lifen, Balzarolo, Melania, Robinson, Emma L., Lorenz, Vera, Della Verde, Giacomo, Joray, Lydia, Mochizuki, Michika, Kaufmann, Beat A., Valstar, Gideon, De Jager, Saskia C.A., Den Ruijter, Hester M., Heymans, Stephane, Pfister, Otmar, Kuster, Gabriela M., Cardiologie, Hart- en Vaatziekten Team A, Experimentele Afd. Cardiologie 1, Experimentele Afd. Cardiologie 2, Circulatory Health, Onderzoek Vrouw Hart & Vaatziekten, Xu, Lifen, Balzarolo, Melania, Robinson, Emma L., Lorenz, Vera, Della Verde, Giacomo, Joray, Lydia, Mochizuki, Michika, Kaufmann, Beat A., Valstar, Gideon, De Jager, Saskia C.A., Den Ruijter, Hester M., Heymans, Stephane, Pfister, Otmar, and Kuster, Gabriela M.

Published
2022

24. Development and validation of a prognostic model for the early identification of COVID-19 patients at risk of developing common long COVID symptoms

Author

Deforth, Manja; https://orcid.org/0000-0002-1111-1799, Gebhard, Caroline E; https://orcid.org/0000-0003-4975-2679, Bengs, Susan; https://orcid.org/0000-0003-2424-3894, Buehler, Philipp K; https://orcid.org/0000-0003-4690-9896, Schuepbach, Reto A; https://orcid.org/0000-0002-7058-4377, Zinkernagel, Annelies S; https://orcid.org/0000-0003-4700-1118, Brugger, Silvio D; https://orcid.org/0000-0001-9492-9088, Acevedo, Claudio T; https://orcid.org/0000-0002-3624-9401, Patriki, Dimitri; https://orcid.org/0000-0001-6364-0927, Wiggli, Benedikt, Twerenbold, Raphael; https://orcid.org/0000-0003-3814-6542, Kuster, Gabriela M, Pargger, Hans, Schefold, Joerg C, Spinetti, Thibaud, Wendel-Garcia, Pedro D; https://orcid.org/0000-0001-7775-3279, Hofmaenner, Daniel A; https://orcid.org/0000-0002-9334-7753, Gysi, Bianca, Siegemund, Martin, Heinze, Georg, Regitz-Zagrosek, Vera; https://orcid.org/0000-0002-3566-3467, Gebhard, Catherine; https://orcid.org/0000-0001-7240-5822, Held, Ulrike; https://orcid.org/0000-0003-3105-5840, Deforth, Manja; https://orcid.org/0000-0002-1111-1799, Gebhard, Caroline E; https://orcid.org/0000-0003-4975-2679, Bengs, Susan; https://orcid.org/0000-0003-2424-3894, Buehler, Philipp K; https://orcid.org/0000-0003-4690-9896, Schuepbach, Reto A; https://orcid.org/0000-0002-7058-4377, Zinkernagel, Annelies S; https://orcid.org/0000-0003-4700-1118, Brugger, Silvio D; https://orcid.org/0000-0001-9492-9088, Acevedo, Claudio T; https://orcid.org/0000-0002-3624-9401, Patriki, Dimitri; https://orcid.org/0000-0001-6364-0927, Wiggli, Benedikt, Twerenbold, Raphael; https://orcid.org/0000-0003-3814-6542, Kuster, Gabriela M, Pargger, Hans, Schefold, Joerg C, Spinetti, Thibaud, Wendel-Garcia, Pedro D; https://orcid.org/0000-0001-7775-3279, Hofmaenner, Daniel A; https://orcid.org/0000-0002-9334-7753, Gysi, Bianca, Siegemund, Martin, Heinze, Georg, Regitz-Zagrosek, Vera; https://orcid.org/0000-0002-3566-3467, Gebhard, Catherine; https://orcid.org/0000-0001-7240-5822, and Held, Ulrike; https://orcid.org/0000-0003-3105-5840

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic demands reliable prognostic models for estimating the risk of long COVID. We developed and validated a prediction model to estimate the probability of known common long COVID symptoms at least 60 days after acute COVID-19. Methods: The prognostic model was built based on data from a multicentre prospective Swiss cohort study. Included were adult patients diagnosed with COVID-19 between February and December 2020 and treated as outpatients, at ward or intensive/intermediate care unit. Perceived long-term health impairments, including reduced exercise tolerance/reduced resilience, shortness of breath and/or tiredness (REST), were assessed after a follow-up time between 60 and 425 days. The data set was split into a derivation and a geographical validation cohort. Predictors were selected out of twelve candidate predictors based on three methods, namely the augmented backward elimination (ABE) method, the adaptive best-subset selection (ABESS) method and model-based recursive partitioning (MBRP) approach. Model performance was assessed with the scaled Brier score, concordance c statistic and calibration plot. The final prognostic model was determined based on best model performance. Results: In total, 2799 patients were included in the analysis, of which 1588 patients were in the derivation cohort and 1211 patients in the validation cohort. The REST prevalence was similar between the cohorts with 21.6% (n = 343) in the derivation cohort and 22.1% (n = 268) in the validation cohort. The same predictors were selected with the ABE and ABESS approach. The final prognostic model was based on the ABE and ABESS selected predictors. The corresponding scaled Brier score in the validation cohort was 18.74%, model discrimination was 0.78 (95% CI: 0.75 to 0.81), calibration slope was 0.92 (95% CI: 0.78 to 1.06) and calibration intercept was -0.06 (95% CI: -0.22 to 0.09). Conclusion: The proposed model was validated to id

Published
2022

25. Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections—A prospective cohort study

Author

Lampart, Maurin, primary, Zellweger, Núria, additional, Bassetti, Stefano, additional, Tschudin-Sutter, Sarah, additional, Rentsch, Katharina M., additional, Siegemund, Martin, additional, Bingisser, Roland, additional, Osswald, Stefan, additional, Kuster, Gabriela M., additional, and Twerenbold, Raphael, additional

Published
2022
Full Text
View/download PDF

26. Sex disparities in patients with suspected COVID-19 presenting at an emergency department in Switzerland

Author

Arslani, Ketina, primary, Eken, Ceylan, additional, Tschudin-Sutter, Sarah, additional, Gebhard, Caroline E., additional, Zellweger, Nuria, additional, Bassetti, Stefano, additional, Bingisser, Roland, additional, Lampart, Maurin, additional, Osswald, Stefan, additional, Kuster, Gabriela M., additional, and Twerenbold, Raphael, additional

Published
2022
Full Text
View/download PDF

27. Contributors

Author

Almeida-Porada, Graça, primary, Asatrian, Greg, additional, Atala, Anthony, additional, Badylak, Stephen F., additional, Baptista, Pedro M., additional, Best, Cameron, additional, Bitar, Khalil N., additional, Breuer, Christopher K., additional, Brown, Bryan N., additional, Canadas, Raphaël F., additional, Caplan, Arnold I., additional, Cervelló, Irene, additional, Chen, William C.W., additional, Chen, Dong F., additional, Childers, Martin K., additional, Cho, Kin-Sang, additional, Conti, Claudio J., additional, Crespo-Barreda, A., additional, Del Río, Marcela, additional, Della Verde, Giacomo, additional, Dhal, Abritee, additional, Donnenberg, Albert, additional, Encabo-Berzosa, M.M., additional, Giménez, Ignacio, additional, Goddard, Melissa A., additional, González-Pastor, R., additional, Gottardi, Riccardo, additional, Guan, Xuan, additional, Guerrero-Aspizua, Sara, additional, Guo, Chenying, additional, Hardy, Winters, additional, Herman, Ira M., additional, Hwang, Catalina K., additional, Iglesias, M., additional, Ignacio, Glicerio, additional, James, Aaron W., additional, Khanh Vu, Thi H., additional, Kikyo, Nobuaki, additional, Kurtzberg, Joanne, additional, Kuster, Gabriela M., additional, Lanas, Angel, additional, Langhans, Mark T., additional, Larcher, Fernando, additional, Lee, Avione Y., additional, Lee, Yong-Ung, additional, Liao, Ronglih, additional, Liou, Jr-Jiun, additional, Mack, David L., additional, Mahler, Nathan, additional, Marques, Alexandra P., additional, Marra, Kacey G., additional, Martin-Duque, P., additional, Meade, Patricia, additional, Medrano, Jose Vicente, additional, Moran, Emma, additional, Oliveira, Joaquim M., additional, Ortíz-Teba, P., additional, Péault, Bruno, additional, Pfister, Otmar, additional, Pina, Sandra, additional, Porada, Christopher D., additional, Reis, Rui L., additional, Rubin, J. Peter, additional, Sabin, Keith, additional, Sánchez-Romero, Natalia, additional, Santamaria, Alvaro, additional, Serrano, J.L., additional, Sheets, Anthony R., additional, Simón, Carlos, additional, Soker, Shay, additional, Soo, Chia, additional, Sun, Jessica M., additional, Talib, Mays, additional, Tara, Shuhei, additional, Ting, Kang, additional, Tuan, Rocky S., additional, Valentin, Jolene E., additional, Vyas, Dipen, additional, Wang, Bo, additional, Wertheim, Jason A., additional, Yu, Honghua, additional, Zakhem, Elie, additional, Zapatero-Solana, Elisabeth, additional, Zhang, Nan, additional, and Zhang, Yuanyuan, additional

Published
2016
Full Text
View/download PDF

29. Additional file 4 of Development and validation of a prognostic model for the early identification of COVID-19 patients at risk of developing common long COVID symptoms

Author

Deforth, Manja, Gebhard, Caroline E., Bengs, Susan, Buehler, Philipp K., Schuepbach, Reto A., Zinkernagel, Annelies S., Brugger, Silvio D., Acevedo, Claudio T., Patriki, Dimitri, Wiggli, Benedikt, Twerenbold, Raphael, Kuster, Gabriela M., Pargger, Hans, Schefold, Joerg C., Spinetti, Thibaud, Wendel-Garcia, Pedro D., Hofmaenner, Daniel A., Gysi, Bianca, Siegemund, Martin, Heinze, Georg, Regitz-Zagrosek, Vera, Gebhard, Catherine, and Held, Ulrike

Abstract

Additional file 4. Logistic regression model based on the ABE and ABESS variable selection, calculated on the total cohort.

Published
2022
Full Text
View/download PDF

30. Pulmonary Surfactant Proteins are Inhibited by IgA Autoantibodies in Severe COVID-19

Author

Sinnberg, Tobias, Lichtensteiger, Christa, Hasan Ali, Omar, Pop, Oltin T, Jochum, Ann-Kristin, Risch, Lorenz, Brugger, Silvio D, Velic, Ana, Bomze, David, Kohler, Philipp, Vernazza, Pietro, Albrich, Werner C, Kahlert, Christian R, Abdou, Maire-Therese, Wyss, Nina, Hofmeister, Kathrin, Niessner, Heike, Zinner, Carl, Gilardi, Mara, Tzankov, Alexandar, Röcken, Martin, Dulovic, Alex, Mairpady Shambat, Srikanth, Ruetalo, Natalia, Buehler, Philipp K, Scheier, Thomas C, Jochum, Wolfram, Kern, Lukas, Henz, Samuel, Schneider, Tino, Kuster, Gabriela M, Lampart, Maurin, Siegemund, Martin, Bingisser, Roland, Schindler, Michael, Schneiderhan-Marra, Nicole, Kalbacher, Hubert, McCoy, Kathy D, Spengler, Werner, Brutsche, Martin H, Macek, Boris, Twerenbold, Raphael, Penninger, Josef M, Matter, Matthias S, and Flatz, Lukas

Subjects
610 Medicine & health
Abstract

RATIONALE Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome with fatal outcomes. Evidence suggests that dysregulated immune responses, including autoimmunity, are key pathogenic factors. OBJECTIVES To assess whether IgA autoantibodies target lung-specific proteins and contribute to disease severity. METHODS We collected 147 blood, 9 lung tissue, and 36 bronchoalveolar lavage fluid samples from three tertiary hospitals in Switzerland and one in Germany. Severe COVID-19 was defined by the need to administer oxygen. We investigated the presence of IgA autoantibodies and their effects on pulmonary surfactant in COVID-19 using the following methods: immunofluorescence on tissue samples, immunoprecipitations followed by mass spectrometry on bronchoalveolar lavage fluid samples, enzyme-linked immunosorbent assays on blood samples, and surface tension measurements with medical surfactant. MEASUREMENTS AND MAIN RESULTS IgA autoantibodies targeting pulmonary surfactant proteins B and C were elevated in patients with severe COVID-19, but not in patients with influenza or bacterial pneumonia. Notably, pulmonary surfactant failed to reduce surface tension after incubation with either plasma or purified IgA from patients with severe COVID-19. CONCLUSIONS Our data suggest that patients with severe COVID-19 harbor IgA against pulmonary surfactant proteins B and C and that these antibodies block the function of lung surfactant, potentially contributing to alveolar collapse and poor oxygenation. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Published
2022
Full Text
View/download PDF

31. Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice

Author

Della Verde, Giacomo, Mochizuki, Michika, Lorenz, Vera, Roux, Julien, Xu, Lifen, Ramin-Wright, Leandra, Pfister, Otmar, and Kuster, Gabriela M

Subjects
Stem Cells, Neovascularization, Physiologic, hemic and immune systems, Antigens, CD34, Cell Differentiation, Hematopoietic Stem Cells, Models, Biological, Immunophenotyping, Mice, fluids and secretions, fms-Like Tyrosine Kinase 3, hemic and lymphatic diseases, Gene Knockdown Techniques, embryonic structures, Animals, Cell Lineage, Side-Population Cells, Research Articles, Biomarkers, Research Article
Abstract

This work shows that Flt3 signaling regulates the composition and functionality of the cardiac side population, which could be relevant for cardiovascular homeostasis under Flt3-inhibitory therapies., Fms-like tyrosine kinase 3 (Flt3) is a regulator of hematopoietic progenitor cells and a target of tyrosine kinase inhibitors. Flt3-targeting tyrosine kinase inhibitors can have cardiovascular side effects. Flt3 and its ligand (Flt3L) are expressed in the heart, but little is known about their physiological functions. Here, we show that cardiac side population progenitor cells (SP-CPCs) from mice produce and are responsive to Flt3L. Compared with wild-type, flt3L−/− mice have less SP-CPCs with less contribution of CD45−CD34+ cells and lower expression of genes related to epithelial-to-mesenchymal transition, cardiovascular development and stem cell differentiation. Upon culturing, flt3L−/− SP-CPCs show increased proliferation and less vasculogenic commitment, whereas Akt phosphorylation is lower. Notably, proliferation and differentiation can be partially restored towards wild-type levels in the presence of alternative receptor tyrosine kinase-activating growth factors signaling through Akt. The lower vasculogenic potential of flt3L−/− SP-CPCs reflects in decreased microvascularisation and lower systolic function of flt3L−/− hearts. Thus, Flt3 regulates phenotype and function of murine SP-CPCs and contributes to cellular and molecular properties that are relevant for their cardiovasculogenic potential.

Published
2021

32. Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

Author

Da Costa Gomes, Clarissa Pedrosa, Ágg, Bence, Andova, Andrejaana, Arslan, Serdal, Baker, Andrew, Barteková, Monika, Beis, Dimitris, Betsou, Fay, Bezzina Wettinger, Stephanie, Bugarski, Branko, Condorelli, Gianluigi, Da Silva, Gustavo José Justo, Danilin, Sabrina, De Gonzalo-Calvo, David, Buil, Alfonso, Carmo-Fonseca, Maria, Enguita, Francisco J., Felekkis, Kyriacos, Ferdinandy, Peter, Gyöngyösi, Mariann, Hackl, Matthias, Karaduzovic-Hadziabdic, Kanita, Hellemans, Jan, Heymans, Stephane, Hlavackova, Markéta, Hoydal, Morten Andre, Jankovic, Aleksandra, Jusic, Amela, Kardassis, Dimitris, Kerkelä, Risto, Kuster, Gabriela M., Lakkisto, Päivi, Leszek, Przemyslaw, Lustrek, Mitja, Maegdefessel, Lars, Martelli, Fabio, Novella, Susana, O’Brien, Timothy, Papaneophytou, Christos, Pedrazzini, Thierry, Pinet, Florence, Popescu, Octavian, Potoˇcnjak, Ines, Robinson, Emma L., Sasson, Shlomo, Scholz, Markus, Simionescu, Maya, Stoll, Monika, Varga, Zoltan V., Vinciguerra, Manlio, Xuereb, Angela, Yilmaz, Mehmet Birhan, Emanueli, Costanza, Devaux, Yvan, Formosa, Melissa Marie, EU-CardioRNA COST Action (CA17129), Repositório da Universidade de Lisboa, Luxembourg Institute of Health (LIH), Semmelweis University [Budapest], Jozef Stefan Institute [Ljubljana] (IJS), Cumhuriyet University [Sivas, Turkey], Queen's Medical Researche Institute, University of Edinburgh, Slovak Academy of Sciences (SAS), Biomedical Research Foundation of the Academy of Athens (BRFAA), Integrated BioBank of Luxembourg (IBBL), University of Malta [Malta], Faculty of Technology and Metallurgy [University of Belgrade], University of Belgrade [Belgrade], Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Oslo University Hospital [Oslo], University of Oslo (UiO), Firalis SAS, Spanish National Research Council (CSIC), Universidade de Lisboa (ULISBOA), University of Cyprus [Nicosia], Medizinische Universität Wien = Medical University of Vienna, International University of Sarajevo, Maastricht University [Maastricht], Czech Academy of Sciences [Prague] (CAS), Norwegian University of Science and Technology [Trondheim] (NTNU), Norwegian University of Science and Technology (NTNU), Institute for Biological Research Sinisa Stankovic [Belgrade] (IBISS), University of Tuzla, University of Crete [Heraklion] (UOC), Institute of Molecular Biology and Biotechnology (IMBB-FORTH), Foundation for Research and Technology - Hellas (FORTH), University of Oulu, University Hospital Basel [Basel], University of Basel (Unibas), Minerva Foundation Institute for Medical Research, Karolinska Institutet [Stockholm], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Universitat de València (UV), National University of Ireland [Galway] (NUI Galway), Université de Lausanne (UNIL), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Babes-Bolyai University [Cluj-Napoca] (UBB), The Hebrew University of Jerusalem (HUJ), Leipzig University, Institute of Cellular Biology and Pathology Nicolae Simionescu, Westfälische Wilhelms-Universität Münster (WWU), Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), National Heart and Lung Institute [London] (NHLI), Royal Brompton and Harefield NHS Foundation Trust-Imperial College London, EU-CardioRNA COST Action (CA17129), European Cooperation in Science and Technology, [Gomes, Clarissa Pedrosa da Costa -- Devaux, Yvan] Luxembourg Inst Hlth, Cardiovasc Res Unit, L-1445 Strassen, Luxembourg -- [Agg, Bence -- Ferdinandy, Peter -- Varga, Zoltan V.] Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, H-1085 Budapest, Hungary -- [Andova, Andrejaana -- Lustrek, Mitja] Jozef Stefan Inst, Dept Intelligent Syst, Ljubljana 1000E, Slovenia -- [Arslan, Serdal] Cumhuriyet Univ, Fac Med, Dept Med Biol, TR-58140 Sivas, Turkey -- [Baker, Andrew] Univ Edinburgh, Ctr Cardiovasc Sci, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland -- [Bartekova, Monika] Slovak Acad Sci, Ctr Expt Med, Inst Heart Res, Bratislava 84104, Slovakia -- [Beis, Dimitris] Acad Athens, Biomed Res Fdn, Athens 11527, Greece -- [Betsou, Fay] Integrated BioBank Luxembourg, L-3550 Dudelange, Luxembourg -- [Wettinger, Stephanie Bezzina -- Xuereb, Angela] Univ Malta, Fac Hlth Sci, MSD-2080 Msida, Malta -- [Bugarski, Branko] Univ Belgrade, Fac Technol & Met, Belgrade 11000, Serbia -- [Condorelli, Gianluigi] Humanitas Res Hosp, Dept Cardiovasc, I-20089 Rozzano, Italy -- [da Silva, Gustavo Jose Justo] Oslo Univ Hosp, Inst Expt Med Res, PB 4956 Nydalen, NO-0424 Oslo, Norway -- [da Silva, Gustavo Jose Justo] Univ Oslo, PB 4956 Nydalen, NO-0424 Oslo, Norway -- [Danilin, Sabrina] Firalis, F-68330 Huningue, France -- [de Gonzalo-Calvo, David] CSIC, Inst Biomed Res Barcelona IIBB, Barcelona 08036, Spain -- [Buil, Alfonso] Mental Hlth Ctr Sct Hans, DK-4000 Roskilde, Denmark -- [Carmo-Fonseca, Maria -- Enguita, Francisco J.] Univ Lisbon, Fac Med, Inst Med Mol, P-1649028 Lisbon, Portugal -- [Felekkis, Kyriacos -- Papaneophytou, Christos] Univ Nicosia, Sch Sci & Engn, Dept Life & Hlth Sci, CY-2417 Nicosia, Cyprus -- [Gyoengyoesi, Mariann] Med Univ Vienna, Dept Cardiol, A-1090 Vienna, Austria -- [Hackl, Matthias] TAmiRNA, A-1190 Vienna, Austria -- [Karaduzovic-Hadziabdic, Kanita] Int Univ Sarajevo, Fac Engn & Nat Sci, Sarajevo 71210, Bosnia & Herceg -- [Hellemans, Jan] Biogazelle, B-9052 Zwijnaarde, Belgium -- [Heymans, Stephane] Maastricht Univ, Fac Hlth Med & Life Sci, Sch Cardiovasc Dis, NL-6229 ER Maastricht, Netherlands -- [Hlavackova, Marketa] Czech Acad Sci, Inst Physiol, Dept Dev Cardiol, Prague 14220, Czech Republic -- [Hoydal, Morten Andre] NTNU Norwegian Univ Technol & Sci, Fac Med & Hlth Sci, Dept Circulat & Med Imaging, NO-7489 Trondheim, Norway -- [Jankovic, Aleksandra] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Physiol, Belgrade 11000, Serbia -- [Jusic, Amela] Univ Tuzla, Fac Nat Sci & Math, Dept Biol, Tuzla 75000, Bosnia & Herceg -- [Kardassis, Dimitris] Univ Crete, Med Sch, Dept Basic Sci, Iraklion 71003, Crete, Greece -- [Kardassis, Dimitris] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71003, Crete, Greece -- [Kerkela, Risto] Univ Oulu, Res Unit Biomed, Oulu 90014, Finland -- [Kuster, Gabriela M.] Univ Hosp, Dept Biomed & Clin Cardiol, CH-4031 Basel, Switzerland -- [Kuster, Gabriela M.] Univ Basel, CH-4031 Basel, Switzerland -- [Lakkisto, Paivi] Minerva Fdn, Helsinki 00290, Finland -- [Leszek, Przemyslaw] Cardinal Stefan Wyszynski Inst Cardiol, PL-04628 Warsaw, Poland -- [Maegdefessel, Lars] Karolinska Inst, Ctr Mol Med, S-17176 Stockholm, Sweden -- [Martelli, Fabio] IRCCS Policlin San Donato, Mol Cardiol Lab, I-20097 Milan, Italy -- [Novella, Susana] Univ Valencia, Dept Physiol, Valencia 46010, Spain -- [Novella, Susana] INCLIVA Biomed Res Inst INCLIVA, Valencia 46010, Spain -- [O'Brien, Timothy] Natl Univ Ireland Galway, Regenerat Med Inst REMEDI, Galway H91 TK33, Ireland -- [Pedrazzini, Thierry] Univ Lausanne, Med Sch, Dept Cardiovasc Med, Expt Cardiol Unit,Div Cardiol, CH-1011 Lausanne, Switzerland -- [Pinet, Florence] Inst Pasteur, INSERM, F-59019 Lille, France -- [Popescu, Octavian] Babes Bolyai Univ, Cluj Napoca 400084, Romania -- [Potocnjak, Ines] Univ Hosp Ctr Sisters Char, Inst Clin Med Res & Educ, Zagreb 10000, Croatia -- [Robinson, Emma] Maastricht Univ, Fac Hlth Med & Life Sci, Ctr Heart Failure Res, Dept Cardiol, NL-6229 ER Maastricht, Netherlands -- [Sasson, Shlomo] Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel -- [Scholz, Markus] Univ Leipzig, Med Fac, Inst Med Informat Stat & Epidemiol, D-04107 Leipzig, Germany -- [Simionescu, Maya] Inst Cellular Biol & Pathol Nicolae Simionescu, Bucharest 050568, Romania -- [Stoll, Monika] Westfalische Wilhelms Univ Munster, Inst Human Genet, Dept Genet Epidemiol, D-48149 Munster, Germany -- [Vinciguerra, Manlio] Int Clin Res Ctr, Brno 65691, Czech Republic -- [Yilmaz, Mehmet Birhan] Dokuz Eylul Univ, Fac Med, Dept Cardiol, TR-35340 Izmir, Turkey -- [Emanueli, Costanza] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, London W12 0HH, England, Hlavackova, Marketa -- 0000-0003-3842-6907, Devaux, Yvan -- 0000-0002-5321-8543, Gyongyosi, Mariann -- 0000-0002-7083-2107, Sasson, Shlomo -- 0000-0002-9343-526X, Buil, Alfonso -- 0000-0002-3097-1014, Hoydal, Morten -- 0000-0003-1804-2578, Justo da Silva, Gustavo -- 0000-0002-1651-7966, Baker, Andrew -- 0000-0003-1441-5576, Lakkisto, Paivi -- 0000-0001-9935-6573, Pinet, Florence -- 0000-0002-5471-1487, Martelli, Fabio -- 0000-0002-8624-7738, Robinson, Emma -- 0000-0002-4866-731X, Novella, Susana -- 0000-0001-8303-7252, Jusic, Amela -- 0000-0003-2835-4284, Beis, Dimitris -- 0000-0003-2579-7848, O'Brien, Timothy -- 0000-0001-9028-5481, Popescu, Octavian -- 0000-0002-2597-7155, Felekkis, Kyriacos -- 0000-0002-0919-0037, de Gonzalo Calvo, David -- 0000-0003-2240-3532, Universidade de Lisboa = University of Lisbon (ULISBOA), University of Cyprus [Nicosia] (UCY), Université de Lausanne = University of Lausanne (UNIL), Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.02 - Cardiomyopathy, RS: CARIM - R2 - Cardiac function and failure, and RS: Carim - H02 Cardiomyopathy

Subjects
Project Report, 0301 basic medicine, medicine.medical_specialty, Biochemistry & Molecular Biology, Knowledge management, lcsh:QH426-470, BIOMARKERS, best practices and guidelines, cardiovascular disease, personalized medicine, transcriptomics, translational research, Context (language use), Translational research, Disease, 030204 cardiovascular system & hematology, Biology, Biochemistry, LONG NONCODING RNAS, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, CIRCULATING MICRORNAS, TARGETS, Genetics, medicine, Cost action, Set (psychology), Molecular Biology, ComputingMilieux_MISCELLANEOUS, Genetics & Heredity, Science & Technology, business.industry, Cardiovascular system -- Diseases, Public health, Medicine -- Research -- International cooperation, 3. Good health, lcsh:Genetics, 030104 developmental biology, Action (philosophy), PERSPECTIVES, Personalized medicine, Translational research, biomedical, business, Transcriptome, Life Sciences & Biomedicine
Abstract

WOS: 000474931400001, PubMed ID: 30934986, Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu)., COST (European Cooperation in Science and Technology) Action EU-CardioRNA [CA17129], This work is supported by COST (European Cooperation in Science and Technology) Action EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action CA17129, CardioRNA.

Published
2019

34. NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction

Author

Xu, Lifen, primary, Balzarolo, Melania, additional, Robinson, Emma L, additional, Lorenz, Vera, additional, Della Verde, Giacomo, additional, Joray, Lydia, additional, Mochizuki, Michika, additional, Kaufmann, Beat A, additional, Valstar, Gideon, additional, de Jager, Saskia C A, additional, den Ruijter, Hester M, additional, Heymans, Stephane, additional, Pfister, Otmar, additional, and Kuster, Gabriela M, additional

Published
2021
Full Text
View/download PDF

35. The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination

Author

Haaf, Philip, primary, Kuster, Gabriela M., additional, Mueller, Christian, additional, Berger, Christoph T., additional, Monney, Pierre, additional, Burger, Peter, additional, Stämpfli, Simon F., additional, Attenhofer Jost, Christine Helena, additional, Zellweger, Michael J., additional, Osswald, Stefan, additional, Donner, Birgit C., additional, Koestner, Simon C., additional, and Tanner, Felix C., additional

Published
2021
Full Text
View/download PDF

36. Defective Desmosomal Adhesion Causes Arrhythmogenic Cardiomyopathy by involving an Integrin-αVβ6/TGF-β Signaling Cascade

Author

Schinner, Camilla, primary, Franz, Henriette, additional, Zimmermann, Aude, additional, Wanuske, Marie-Theres, additional, Geier, Florian, additional, Pelczar, Pawel, additional, Lorenz, Vera, additional, Xu, Lifen, additional, Stuedle, Chiara, additional, Maly, Piotr I, additional, Kauferstein, Silke, additional, Beckmann, Britt Maria, additional, Kuster, Gabriela M, additional, and Spindler, Volker, additional

Published
2021
Full Text
View/download PDF

37. Sex versus gender-related characteristics: which predicts clinical outcomes of acute COVID-19?

Author

Gebhard, Caroline E., Hamouda, Nadia, Gebert, Pimrapat, Regitz-Zagrosek, Vera, Gebhard, Catherine, on behalf of the COGEN Investigators, Bengs, Susan, Gysi, Bianca, Dussault-Cloutier, Arnaud, Buehler, Karl Philipp, Schuepbach, Reto A., Zinkernagel, Annelies S., Brugger, Silvio D., Acevedo, Claudio, Patriki, Dimitri, Wiggli, Benedikt, Beer, Jürg H., Friedl, Andrée, Twerenbold, Raphael, and Kuster, Gabriela M.

Published
2022
Full Text
View/download PDF

39. Understanding the Impact of Sociocultural Gender on Post-acute Sequelae of COVID-19: a Bayesian Approach

Author

Gebhard, Caroline E., primary, Sütsch, Claudia, additional, Bengs, Susan, additional, Todorov, Atanas, additional, Deforth, Manja, additional, Buehler, Karl Philipp, additional, Meisel, Alexander, additional, Schuepbach, Reto A., additional, Zinkernagel, Annelies S., additional, Brugger, Silvio D., additional, Acevedo, Claudio, additional, Patriki, Dimitri, additional, Wiggli, Benedikt, additional, Gysi, Bianca, additional, Beer, Jürg H., additional, Friedl, Andrée, additional, Twerenbold, Raphael, additional, Kuster, Gabriela M., additional, Pargger, Hans, additional, Tschudin-Sutter, Sarah, additional, Schefold, Joerg C., additional, Spinetti, Thibaud, additional, Henze, Chiara, additional, Pasqualini, Mina, additional, Sager, Dominik F., additional, Mayrhofer, Lilian, additional, Grieder, Mirjam, additional, Tontsch, Janna, additional, Franzeck, Fabian, additional, Wendel Garcia, Pedro D., additional, Hofmaenner, Daniel A., additional, Scheier, Thomas, additional, Bartussek, Jan, additional, Haider, Ahmed, additional, Grämer, Muriel, additional, Mikail, Nidaa, additional, Rossi, Alexia, additional, Zellweger, Núria, additional, Opic, Petra, additional, Portmann, Angela, additional, von Känel, Roland, additional, Pazhenkottil, Aju P., additional, Messerli, Michael, additional, Buechel, Ronny R., additional, Kaufmann, Philipp A., additional, Treyer, Valerie, additional, Siegemund, Martin, additional, Held, Ulrike, additional, Regitz-Zagrosek, Vera, additional, and Gebhard, Catherine, additional

Published
2021
Full Text
View/download PDF

41. Understanding the Impact of Sociocultural Gender on Post-acute Sequelae of COVID-19: a Bayesian Approach

Author

Gebhard, Caroline E, Sütsch, Claudia, Bengs, Susan, Deforth, Manja, Buehler, Karl Philipp, Hamouda, Nadia, Meisel, Alexander, Schuepbach, Reto A, Zinkernagel, Annelies S, Brugger, Silvio D, Acevedo, Claudio, Patriki, Dimitri, Wiggli, Benedikt, Beer, Jürg H, Friedl, Andrée, Twerenbold, Raphael, Kuster, Gabriela M, Pargger, Hans, Tschudin-Sutter, Sarah, Schefold, Joerg C, Spinetti, Thibaud, Dussault-Cloutier, Arnaud, Henze, Chiara, Pasqualini, Mina, Sager, Dominik F, Mayrhofer, Lilian, Grieder, Mirjam, Tontsch, Janna, Franzeck, Fabian, Wendel Garcia, Pedro D, et al, and University of Zurich

Subjects
610 Medicine & health, 10181 Clinic for Nuclear Medicine
Published
2021
Full Text
View/download PDF

42. The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination

Author

Haaf, Philip, Kuster, Gabriela M, Mueller, Christian, Berger, Christoph T, Monney, Pierre, Burger, Peter, Stämpfli, Simon F, Attenhofer Jost, Christine Helena, Zellweger, Michael J, Osswald, Stefan, Donner, Birgit C, Koestner, Simon C, Tanner, Felix C, Haaf, Philip, Kuster, Gabriela M, Mueller, Christian, Berger, Christoph T, Monney, Pierre, Burger, Peter, Stämpfli, Simon F, Attenhofer Jost, Christine Helena, Zellweger, Michael J, Osswald, Stefan, Donner, Birgit C, Koestner, Simon C, and Tanner, Felix C

Abstract

The benefits of vaccination - regarding COVID-19 infection and transmission, as well as COVID-associated complications - clearly outweigh the potential risk of vaccine-associated inflammation of the heart and other adverse events. Given the current state of knowledge, the outcome of myocarditis and pericarditis following vaccination is generally good. This review aims to guide physicians in the early diagnosis and management of suspected myocarditis following mRNA COVID vaccination. The initial work-up should include detailed history, a 12-lead electrocardiogram and serological biomarkers (high-sensitivity cardiac troponin T/I, natriuretic peptides and markers of inflammation) in accordance with the assessments recommended in current clinical practice guidelines for patients presenting with acute chest pain. In patients with suspected myocarditis, further assessment with transthoracic echocardiography and cardiovascular magnetic resonance imaging should be undertaken to confirm peri-/myocarditis and to distinguish the findings from other diseases with similar presentation. Patients with mRNA vaccine-associated myocarditis should be followed-up at least once to exclude chronic myocardial inflammation and deterioration of left ventricular ejection fraction. Consultation with an expert such as an immunologist with experience in vaccination regarding further mRNA vaccinations is advised in all patients with mRNA vaccine-associated perimyocarditis. Reporting of mRNA vaccine-associated myocarditis to Swissmedic is mandatory. Cohort studies prospectively follow-up on young adult and paediatric populations following immunisation with an mRNA COVID vaccine to monitor cardiac and immune parameters would generate valuable knowledge to better understand pathogenesis and risk factors for vaccine-associated perimyocarditis.

Published
2021

43. Comparison of Acute Kidney Injury in Patients with COVID-19 and Other Respiratory Infections: A Prospective Cohort Study

Author

Diebold, Matthias, primary, Zimmermann, Tobias, additional, Dickenmann, Michael, additional, Schaub, Stefan, additional, Bassetti, Stefano, additional, Tschudin-Sutter, Sarah, additional, Bingisser, Roland, additional, Heim, Corin, additional, Siegemund, Martin, additional, Osswald, Stefan, additional, Kuster, Gabriela M., additional, Rentsch, Katharina M., additional, Breidthardt, Tobias, additional, and Twerenbold, Raphael, additional

Published
2021
Full Text
View/download PDF

44. Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients

Author

Vischer, Annina S., primary, Kuster, Gabriela M., additional, Twerenbold, Raphael, additional, Pfister, Otmar, additional, Zhou, Qian, additional, Villiger, Andrea, additional, Poglitsch, Marko, additional, Krähenbühl, Stephan, additional, Mayr, Michael, additional, Osswald, Stefan, additional, Haschke, Manuel, additional, and Burkard, Thilo, additional

Published
2021
Full Text
View/download PDF

45. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls

Author

Atila, Cihan, primary, Sailer, Clara O, additional, Bassetti, Stefano, additional, Tschudin-Sutter, Sarah, additional, Bingisser, Roland, additional, Siegemund, Martin, additional, Osswald, Stefan, additional, Rentsch, Katharina, additional, Rueegg, Marco, additional, Schaerli, Sabrina, additional, Kuster, Gabriela M, additional, Twerenbold, Raphael, additional, and Christ-Crain, Mirjam, additional

Published
2021
Full Text
View/download PDF

46. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?

Author

Kuster, Gabriela M, Pfister, Otmar, Burkard, Thilo, Zhou, Qian, Twerenbold, Raphael, Haaf, Philip, Widmer, Andreas F, and Osswald, Stefan

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Discussion Forum, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, 030204 cardiovascular system & hematology, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Viewpoint, Renin–angiotensin system, Medicine, In patient, 030212 general & internal medicine, business, Cardiology and Cardiovascular Medicine
Published
2020
Full Text
View/download PDF

47. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019

Author

Sutter, Raoul, primary, Hert, Lisa, additional, De Marchis, Gian Marco, additional, Twerenbold, Raphael, additional, Kappos, Ludwig, additional, Naegelin, Yvonne, additional, Kuster, Gabriela M., additional, Benkert, Pascal, additional, Jost, Jasmine, additional, Maceski, Aleksandra Maleska, additional, Rüegg, Stephan, additional, Siegemund, Martin, additional, Leppert, David, additional, Tschudin‐Sutter, Sarah, additional, and Kuhle, Jens, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results